The companies have signed an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor. As part of the agreement, Bristol-Myers Squibb can nominate up to two
The approval is based on data from the Phase 3 RESONATE-2 (PCYC-1115) study, the first head-to-head clinical trial comparing IMBRUVICA to a chemotherapy agent. Results showed IMBRUVICA significantly
Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.
All patients who completed 12 weeks of low-dose maintenance therapy were desensitized to levels of peanut protein beyond the 250-300 mg typically found in one peanut kernel. Low-Dose
Remedy Pharmaceuticals CEO Sven Jacobson said: "Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA.. "We are pleased
With no available vaccine or treatment modalities, the World Health Organization (WHO) recently declared Zika virus an international public health emergency. Vaxart’s vaccine platform enables delivery of recombinant
Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive
Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve
The companies plan to start the phase I/Ib clinical trial in the second half of this year. Avelumab, which is Merck’s lead immuno-oncology compound, is a fully human
The BMI uses signals from hundreds of neurons recorded in two regions of the monkeys’ brains that are involved in sensation and movement. Remarkably as animals think about
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.